Acute Heart Failure Management GuidelinesAKI or significant CKD 5.0 Hx of angioedema (ACEI) Hold for...

12
Acute Heart Failure Management Guidelines

Transcript of Acute Heart Failure Management GuidelinesAKI or significant CKD 5.0 Hx of angioedema (ACEI) Hold for...

Page 1: Acute Heart Failure Management GuidelinesAKI or significant CKD 5.0 Hx of angioedema (ACEI) Hold for anesthesia & dye studies AKI or significant CKD or K > 5.0 ACEI within 36 hrs

Acute Heart Failure Management Guidelines

Page 2: Acute Heart Failure Management GuidelinesAKI or significant CKD 5.0 Hx of angioedema (ACEI) Hold for anesthesia & dye studies AKI or significant CKD or K > 5.0 ACEI within 36 hrs

BackgroundMulti-disciplinary group convened to address the

challenges in caring for heart failure patients

This collaborative regional team focused on:–Improvement of our NYP Heart Failure services–Patient and physician education–Online resources–Innovation around transitions of care

2

Page 3: Acute Heart Failure Management GuidelinesAKI or significant CKD 5.0 Hx of angioedema (ACEI) Hold for anesthesia & dye studies AKI or significant CKD or K > 5.0 ACEI within 36 hrs

Purpose of CHF Management GuidelinesStandardize CHF Care across NYP’s 8 Hospital System

Provide excellent care to all heart failure patients admitted to the hospital through:–Decongestion with intravenous diuretics–Rapid evaluation for decompensation–Guidance for cardiology and/or heart failure

consultation/referral –Discharge planning

3

Page 4: Acute Heart Failure Management GuidelinesAKI or significant CKD 5.0 Hx of angioedema (ACEI) Hold for anesthesia & dye studies AKI or significant CKD or K > 5.0 ACEI within 36 hrs

Standardized Yet Campus Specific

4

• Heart Failure Management Guidelines cards are campus specific

• Medications listed reflect campus formulary

• Accurate phone and beeper numbers for cardiology and advanced heart failure consults and referrals

Page 5: Acute Heart Failure Management GuidelinesAKI or significant CKD 5.0 Hx of angioedema (ACEI) Hold for anesthesia & dye studies AKI or significant CKD or K > 5.0 ACEI within 36 hrs
Page 6: Acute Heart Failure Management GuidelinesAKI or significant CKD 5.0 Hx of angioedema (ACEI) Hold for anesthesia & dye studies AKI or significant CKD or K > 5.0 ACEI within 36 hrs
Page 7: Acute Heart Failure Management GuidelinesAKI or significant CKD 5.0 Hx of angioedema (ACEI) Hold for anesthesia & dye studies AKI or significant CKD or K > 5.0 ACEI within 36 hrs
Page 8: Acute Heart Failure Management GuidelinesAKI or significant CKD 5.0 Hx of angioedema (ACEI) Hold for anesthesia & dye studies AKI or significant CKD or K > 5.0 ACEI within 36 hrs
Page 9: Acute Heart Failure Management GuidelinesAKI or significant CKD 5.0 Hx of angioedema (ACEI) Hold for anesthesia & dye studies AKI or significant CKD or K > 5.0 ACEI within 36 hrs
Page 10: Acute Heart Failure Management GuidelinesAKI or significant CKD 5.0 Hx of angioedema (ACEI) Hold for anesthesia & dye studies AKI or significant CKD or K > 5.0 ACEI within 36 hrs

Where can I find the card?

10

https://www.nyp.org/heart/chf-hub

Mobile Heartbeat

Physical CardElectronic PDF

Page 11: Acute Heart Failure Management GuidelinesAKI or significant CKD 5.0 Hx of angioedema (ACEI) Hold for anesthesia & dye studies AKI or significant CKD or K > 5.0 ACEI within 36 hrs

11

Page 12: Acute Heart Failure Management GuidelinesAKI or significant CKD 5.0 Hx of angioedema (ACEI) Hold for anesthesia & dye studies AKI or significant CKD or K > 5.0 ACEI within 36 hrs

Thank You

12


ARANCEL CKD

ARANCEL CKD

HTN CKD - KDIGO · Basis for Discontinuing ACEi in Advanced CKD Observational Study • 52 patients (1/2 DM) stages 4 and 5 CKD observed year before and year after stopping ACEi/ARB

HTN CKD - KDIGO · Basis for Discontinuing ACEi in Advanced CKD Observational Study • 52 patients (1/2 DM) stages 4 and 5 CKD observed year before and year after stopping ACEi/ARB

1. 2 ACEI inhibit angiotensin converting enzyme in the body. ACEI inhibit angiotensin converting enzyme in the body. Enzyme maintains balance between:

1. 2 ACEI inhibit angiotensin converting enzyme in the body. ACEI inhibit angiotensin converting enzyme in the body. Enzyme maintains balance between:

ckd bp.pdf

ckd bp.pdf

CKD Presentation

CKD Presentation

ACEI Irish Water Presentation 03 04 14

ACEI Irish Water Presentation 03 04 14

Kyoto ACEI Deaccessioning Srakar _1

Kyoto ACEI Deaccessioning Srakar _1

ACEI of Trichoderma reesei Is a Repressor of Cellulase and

ACEI of Trichoderma reesei Is a Repressor of Cellulase and

CKD CKDR CKD/EW CKDR/EW

CKD CKDR CKD/EW CKDR/EW

St Pancras Community CKD Service - London …€¦ · Community CKD Service • CKD pathway agreed with 3 locality GP CKD leads • Established referral criteria • EMIS records

St Pancras Community CKD Service - London …€¦ · Community CKD Service • CKD pathway agreed with 3 locality GP CKD leads • Established referral criteria • EMIS records

2010 ACEI Conference Presentation Navigating the Journaling Maze Ann Stillwagon

2010 ACEI Conference Presentation Navigating the Journaling Maze Ann Stillwagon

Resistance HTN & ACEI vs ARB

Resistance HTN & ACEI vs ARB

Essentials of CKD Comorbidities and outcomes in CKD.

Essentials of CKD Comorbidities and outcomes in CKD.

FrontCover Section 7 - Energex...SEC CKD CKD )

FrontCover Section 7 - Energex...SEC CKD CKD )

CKD & HT...2018/02/22  · • CKD 2 eGFR 60-89 mild • CKD 3a eGFR 45-59 mild-moderate • CKD 3b eGFR 30-44 moderate • CKD 4 eGFR 15-29 severe • CKD 5 eGFR

CKD & HT...2018/02/22  · • CKD 2 eGFR 60-89 mild • CKD 3a eGFR 45-59 mild-moderate • CKD 3b eGFR 30-44 moderate • CKD 4 eGFR 15-29 severe • CKD 5 eGFR

Four multi-channel models: CKd-604, CKd-608, CKd-1204 and ...

Four multi-channel models: CKd-604, CKd-608, CKd-1204 and ...

Angiotensin Converting Enzyme inhibitor (ACEI)

Angiotensin Converting Enzyme inhibitor (ACEI)

Congratulations on the 35 th Anniversary Conference of the ACEI-Philippines From All Members of ACEI Executive Board Hong Kong & Macau Welcome to Hong.

Congratulations on the 35 th Anniversary Conference of the ACEI-Philippines From All Members of ACEI Executive Board Hong Kong & Macau Welcome to Hong.

CKD Pulmonary

CKD Pulmonary

Ckd Micro1

Ckd Micro1